Long-Term Data from CANbridge Pharmaceuticals CAN008 Phase 1/2 Trial in Glioblastoma Multiforme Shows 67% Five-Year Overall Survival Rate Compared to 8.2% in Institutional Database
Data to be Presented at the ESMO Sarcoma and Rare Cancers Annual Congress 83% overall survival at two years vs....




















